Actualités

BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.

Retirees evaluating dividend funds tend to anchor on current yield, which is exactly why Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) often gets overlooked. The fund pays a distribution yield of roughly 1.6%, which looks unimpressive next to higher-yielding alternatives. Morningstar analysts have repeatedly flagged VIG as a quiet winner for retirees precisely because of that misread. ... Vanguard’s VIG Quietly Returned 247% While Investors Chased Higher Yields

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist. Sp

Bristol Myers Squibb (NYSE:BMY) is rolling out Anthropic's Claude enterprise AI across its global operations. The company is broadening its neuroscience focus after a US$14b acquisition, adding drug candidates for schizophrenia and Alzheimer's disease. These moves reflect a shift toward large scale AI use in pharma and a wider footprint beyond oncology. Bristol Myers Squibb is a large pharmaceutical company best known for its work in oncology and immunology. A full scale deployment of...

Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak

The market appears to be short-sighted.

BMS will roll out Claude to over 30,000 employees, targeting three main areas for near-term impact.

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic ‌to make its Claude AI model ‌available to over 30,000 employees in an effort to ​accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its ‌use in research, ⁠drug development, manufacturing and other commercial and medical affairs. • Agentic ​AI, which ​requires little human intervention, could increase clinical development productivity by about 35% to 45% ​over the ‌next five years, consultancy McKinsey said last ​year.

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

The deal helps solidify Anthropic’s commitment to the life sciences sector as it targets more enterprise clients.

Recent price target moves for Bristol-Myers Squibb, including adjustments to US$70, US$75 and US$60, sit against only a very small shift in one fair value estimate from US$63.04 to US$62.96. These changes reflect how differently analysts are weighing execution risk, late-stage pipeline potential and the impact of upcoming patent expiries when thinking about where the stock could trade next. As you read on, you will see how to make sense of this evolving narrative and what to watch as new data...

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

Bristol Myers Squibb (NYSE:BMY) is investing US$1b in a new manufacturing facility in Houston, aimed at expanding pharmaceutical production capacity and creating hundreds of local jobs. The company has also launched a collaboration with the Tigerlily Foundation focused on improving clinical trial access and health equity for underrepresented patient groups. Bristol Myers Squibb is a global biopharmaceutical company focused on developing and manufacturing treatments across oncology,...

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o

Tempus AI Inc. announced a new collaboration initiative with Bristol Myers Squibb Co. aimed at improving clinical trial design and increasing the Probability of Technical & Regulatory Success across five initial development programs. The companies plan to use artificial intelligence,...

These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them.

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.